Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. Issue 4 (16th August 2017)

• Record Type: Journal Article
• Authors: Hindryckx, Pieter; Novak, Gregor; Bonovas, Stefanos; Peyrin‐Biroulet, Laurent; Danese, Silvio
• Is Part Of: Clinical pharmacology & therapeutics. Volume 102:Issue 4(2017)
• Page Start: 633
• Page End: 641
• Publication Date: 2017-08-16
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.791
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).